- AU$149.74m
- AU$106.76m
- AU$16.23m
Australia's Orthocell jumps on surgical adoption of nerve repair device
Brief: Orthocell Ltd Records Revenue Of A$2.73 Million For June Quarter
Brief: Orthocell Appoints Jim Piper As CFO
Australia's Orthocell rises on strong June quarter revenue, upbeat US outlook
Brief: Orthocell Posts Revenue Of A$2.73 Million For June Quarter
Australia's Orthocell rises after new product used in US surgery
Brief: Orthocell Says 12 Distributors Signed For Remplir Covering 21 States In US
Australia's Orthocell rises on regulatory nod to begin sales in Canada
Brief: Orthocell Seeks Trading Halt
Australia's Orthocell advances on product approval in Thailand
Brief: Orthocell Says Remplir Approved To Commence Sales
Brief: Orthocell Says First U.S. Distributors Signed For Remplirs
Australia's Orthocell rises as co secures US distributors for flagship product
Australia's Orthocell rises on sales approval application in Hong Kong
Brief: Orthocell Submits Regulatory Application To Commence Sales Of Remplir In Hong Kong
Brief: Orthocell Receives Regulatory Approval For Striate+ In Brazil
Australia's Orthocell rises on FDA nod for US launch of nerve repair drug
Brief: Orthocell Says Got US FDA 510(K) Clearance For Remplir To Commence Commercial Distribution
Brief: Orthocell Seeks Trading Halt